<DOC>
	<DOC>NCT00651807</DOC>
	<brief_summary>This trial is conducted to evaluate the effect of etonogestrel in comparison to placebo on: - the prostate volume and the urinary complaints; - the urinary flow and the urinary volume in the bladder after voiding; - the progression of the disease; - the sexual function, well-being and urinary complaints-related Quality of Life. In addition the safety and the way the drug is absorbed and excreted by the body will be analyzed.</brief_summary>
	<brief_title>A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>Signed written informed consent, obtained before screening evaluations; Men diagnosed with LUTS suggestive of BPH: Baseline IPSS score of = 12 (moderate to severe); Prostate volume of = 40 mL and &lt; 100 mL (based on TRUS); Peak urinary flow rate = 15 mL/s with a voided volume of =125 mL Age at least 50 but not older than 80 years at screening PSA &lt; 10 ng/mL and exclusion of prostate cancer to the satisfaction of the investigator (e.g. by biopsy) A post void residual volume &gt;250 mL Use of drugs interfering with efficacy assessments within two weeks or six months prior to start treatment (depending on drug) Acute urinary retention within the past 12 months History of surgery for BPH, including other minimally invasive procedures Presence of urinary tract infection Presence or history of (subclinical) prostate cancer, bladder cancer, urethral stricture, or pelvic irradiation Cardiac or cerebrovascular event within the past six months Presence or history of any neurological disease associated with primary bladder dysfunction Presence or history of liver/renal disease or disturbance of liver/renal function that failed to return to normal Clinically relevant abnormal laboratory result as judged by the (sub)investigator</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>